Hoosier Cancer Research Network has released a new report, “Investigator-Initiated Oncology Trials: Trends, Challenges, and Opportunities,” that captures the experience and perspectives of more than 130 researchers across its nationwide network. The findings highlight key trends shaping investigator-initiated oncology research and the operational, institutional, and funding challenges researchers face in today’s environment.
Based on a late 2024 survey conducted across HCRN’s network, the report reveals data that underscores the state of investigator-initiated trials (IITs), clinical studies initiated and managed by non-industry investigators (typically academic or independent researchers) who assume the sponsor role. These studies are designed to answer pressing clinical questions, expand therapeutic knowledge, and drive innovation in patient care.
“More than half of researchers, 58%, said their IITs have had a positive influence, shaped national treatment guidelines, or supported new drug registrations,” said Brian Stemme, chief executive officer of HCRN. “These findings highlight the significant role IITs often play in addressing unmet needs in clinical practice, even as investigators navigate the complexities of funding and trial activation.”
Chris Fausel, chair of the HCRN Board of Directors, emphasized the role HCRN has long played in supporting researchers at every level.
“For decades, HCRN has worked closely with researchers, institutions, and funders to answer important clinical questions that are ideally answered through multi-center IITs,” said Fausel. “This new report captures both the opportunities and the obstacles that affect how these trials are conducted and reinforces HCRN’s role.”
The survey was conducted prior to recent changes in federal research funding and does not reflect the potential impact of these changes. However, these shifts underscore the urgency of aligning resources and collaborative platforms to support the future of IITs.
The complete report offers a comprehensive, data-driven look at the state of investigator-initiated trials and the trends shaping their future. Fill out the form below to access the insights and commentary that can help advance your own clinical research efforts.
Access the full HCRN IIT Report
Access the full HCRN IIT Report
About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
